Active Biotech
0.448 SEK -0.33%1 investor is following this company
Active Biotech develops drugs in disease areas such as cancer and inflammatory diseases where the immune system plays a crucial role. The company's project portfolio contains both small orally active immunomodulatory molecules and antibody-based immunotherapy. The company focuses on projects in specialist indications in disease areas such as hematological cancer, inflammatory eye diseases, and solid tumors.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ACTI
Daily low / high price
0.441 / 0.457
SEK
Market cap
162.09M SEK
Turnover
45.58K SEK
Volume
102K
Latest videos
Financial calendar
Interim report
07.11.2024
Annual report
13.02.2025
Interim report
08.05.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
MGA Holding AB | 28.1 % | 28.1 % |
Sjuenda Holding | 7.4 % | 7.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Active Biotech Interim Report Q2 2024
Active Biotech provides update on the clinical phase Ib/IIa study with tasquinimod in relapsed refractory multiple myeloma
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools